Which immunosuppressive drugs constitute the core therapy for renal transplant recipients?

• A. Beta blockers, ACE inhibitors, diuretics.
• B. Calcineurin inhibitors (e.g., cyclosporine, tacrolimus), steroids, mycophenolate/azathioprine.
• C. Antibiotics only.
• D. Immunotherapy only.

Answer: (B)

The key idea here is identifying the standard maintenance immunosuppressive regimen used after kidney transplantation to prevent rejection. This commonly includes calcineurin inhibitors (such as cyclosporine or tacrolimus), corticosteroids, and antimetabolites (such as mycophenolate mofetil or azathioprine). Calcineurin inhibitors block T-cell activation by inhibiting IL-2 production, which dampens the T-cell response that would attack the graft. Steroids provide broad immunosuppression, reducing multiple immune pathways involved in rejection. Antimetabolites inhibit lymphocyte proliferation by blocking nucleotide synthesis, limiting the expansion of T and B cells. Using these three classes together targets different points in the immune response, offering effective graft protection with a manageable safety profile for many patients.

Options focused on blood pressure control (beta blockers, ACE inhibitors, diuretics) or on antibiotics do not suppress the immune system and thus aren’t the immunosuppressive backbone used to prevent transplant rejection. Immunotherapy is a broad term and doesn’t specify the standard maintenance combination described above.